This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Human Papillomavirus
and you are
between 12 and 14
years old
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

Two human papillomavirus vaccines are now commercially available. No clinical data exist regarding: - The immunogenicity and safety of Gardasil and Twinrix when co-administered. - The immunogenicity and safety of Cervarix when administered to subjects previously vaccinated with Gardasil. The main objective of the first phase of this clinical trial was: • To assess and compare the immunogenicity of Gardasil and Twinrix Junior when co-administered or administered at one month interval according to a 0, 6 month schedule to 9-10 year-old girls. The main objective of the seconde phase of this clinical trial is: • To determine the effect of a booster dose of Gardasil or Cervarix on HPV antibodies when given 42 months post-vaccination of 9-10 year-old girls with two doses of Gardasil. Study Design & Duration: Experimental Design: Blind for the third HPV vaccine dose, randomized, single centre study with two treatment groups. Duration of the study: Participants will be followed for the duration of 10 years post-primary vaccination. Number of Centres: One Center.

Provided treatments

  • Biological: Gardasil vaccine, Immunogenicity, Booster dose.
  • Biological: Cervarix Vaccine, Immunogenicity, Booster Dose.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01456715. The sponsor of the trial is Laval University and it is looking for 418 volunteers for the current phase.
Official trial title:
Immunogenicity and Safety of Gardasil and Twinrix Vaccines Co-administered or Administered a Month Apart, According to the 0, 6 Months Schedule and the Effect of a Third Dose of Gardasil or Cervarix Administered 42 Months Later.